179 related articles for article (PubMed ID: 35153780)
1. Arylamine
Salazar-González RA; Doll MA; Hein DW
Front Pharmacol; 2022; 13():797469. PubMed ID: 35153780
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Human Arylamine
Butcher NJ; Burow R; Minchin RF
Mol Pharmacol; 2020 Aug; 98(2):88-95. PubMed ID: 32487734
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism.
Carlisle SM; Trainor PJ; Hong KU; Doll MA; Hein DW
Sci Rep; 2020 Jun; 10(1):9804. PubMed ID: 32555504
[TBL] [Abstract][Full Text] [Related]
4. Human Arylamine
Carlisle SM; Trainor PJ; Doll MA; Hein DW
Front Pharmacol; 2021; 12():803254. PubMed ID: 35046826
[TBL] [Abstract][Full Text] [Related]
5. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
Peck B; Chen CY; Ho KK; Di Fruscia P; Myatt SS; Coombes RC; Fuchter MJ; Hsiao CD; Lam EW
Mol Cancer Ther; 2010 Apr; 9(4):844-55. PubMed ID: 20371709
[TBL] [Abstract][Full Text] [Related]
6. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
[TBL] [Abstract][Full Text] [Related]
7. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
[TBL] [Abstract][Full Text] [Related]
8. Deletion of arylamine N-acetyltransferase 1 in MDA-MB-231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis.
Doll MA; Ray AR; Salazar-González RA; Shah PP; Vega AA; Sears SM; Krueger AM; Hong KU; Beverly LJ; Hein DW
Mol Carcinog; 2022 May; 61(5):481-493. PubMed ID: 35133049
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases.
Kyrylenko S; Kyrylenko O; Suuronen T; Salminen A
Cell Mol Life Sci; 2003 Sep; 60(9):1990-7. PubMed ID: 14523559
[TBL] [Abstract][Full Text] [Related]
10. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
Tiang JM; Butcher NJ; Minchin RF
Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of the modulation of sirtuins on arylamine
Turiján-Espinoza E; Salazar-González RA; Uresti-Rivera EE; Hernández-Hernández GE; Ortega-Juárez M; Milán R; Portales-Pérez D
Acta Pharm Sin B; 2018 Mar; 8(2):188-199. PubMed ID: 29719779
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
14. Human
Hein DW; Doll MA; Habil MR
Front Pharmacol; 2022; 13():821133. PubMed ID: 35281898
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.
Hong KU; Tagnedji AH; Doll MA; Walls KM; Hein DW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5047-5060. PubMed ID: 36329350
[TBL] [Abstract][Full Text] [Related]
16. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.
Minchin RF; Butcher NJ
BMC Genomics; 2018 Jul; 19(1):513. PubMed ID: 29969986
[TBL] [Abstract][Full Text] [Related]
17. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.
Wakefield L; Robinson J; Long H; Ibbitt JC; Cooke S; Hurst HC; Sim E
Genes Chromosomes Cancer; 2008 Feb; 47(2):118-26. PubMed ID: 17973251
[TBL] [Abstract][Full Text] [Related]
18. Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype.
Salazar-González RA; Turiján-Espinoza E; Hein DW; Niño-Moreno PC; Romano-Moreno S; Milán-Segovia RC; Portales-Pérez DP
Arch Toxicol; 2018 Feb; 92(2):661-668. PubMed ID: 29043425
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
Paterson S; Sin KL; Tiang JM; Minchin RF; Butcher NJ
Drug Metab Dispos; 2011 Jan; 39(1):77-82. PubMed ID: 20870783
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.
Solomon JM; Pasupuleti R; Xu L; McDonagh T; Curtis R; DiStefano PS; Huber LJ
Mol Cell Biol; 2006 Jan; 26(1):28-38. PubMed ID: 16354677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
